Go to  Advanced Search

YB-1 is a downstream component of the PI3K/Akt signaling pathway and regulates EGFR in breast carcinoma : a mechanism for breast cancer growth

Show full item record

Files in this item

Files Size Format Description   View
ubc_2006-0718.pdf 10.48Mb Adobe Portable Document Format   View/Open
Title: YB-1 is a downstream component of the PI3K/Akt signaling pathway and regulates EGFR in breast carcinoma : a mechanism for breast cancer growth
Author: Wu, Chia-Cheng Joyce
Degree Master of Science - MSc
Program Medical Genetics
Copyright Date: 2006
Abstract: High level of activated or phosphorylated serine/threonine kinase Akt is commonly observed in aggressive breast cancer. Hence, the Akt signaling pathway has become a popular target for therapeutic interventions. Previously our lab discovered that phosphorylated Akt is co-expressed with a transcription/translation factor called the Y-box Binding Protein-1 (YB-1) and that Akt phosphorylates YB-1 at Ser102 in vitro. It was also found that YB-1, but not the YB-1 mutant in which Ser102 is mutated to alanine (YB-1A102), enhanced breast cancer cell growth. Since YB-1 was originally isolated as a DNA binding protein that interacts with the regulatory elements of the epidermal growth factor receptor (EGFR), we addressed the possibility that phosphorylated YB-1 stimulates breast cancer cell growth by up-regulating EGFR expression. First, we demonstrated that YB-1 was phosphorylated through the PI3K/Akt pathway ex vivo by immunoprecipitation and western blotting. We then illustrated that loss of Ser102 affects the nuclear translocation of YB-1, implying that Akt may also regulate YB-1 nuclear trafficking. By exogenously expressing YB-1 or YB-1A102 in breast cancer cell lines we showed that YB-1 but not YB-1A102 induced the levels of EGFR mRNA and protein. It was revealed that YB-1 bound to the -2kb of the EGFR promoter by chromatin immunoprecipitation. Interestingly, disruption of Ser102 prevented YB-1 from interacting with the first 1 kb of the EGFR promoter, indicating that binding to this region by YB-1 is regulated by the PI3K/Akt signaling. We then demonstrated that mutation of Ser 102 perturbed YB-1 from activating the -1kb of the EGFR promoter by luciferase reporter assays. Finally, since activation of Akt depends on 3-phosphoinositide-dependent protein kinase-1 (PDK1), we examined the potential of a PDK1 inhibitor, OSU-03012, to inhibit the functions of YB-1. It was found that OSU-03012 blocked YB-1 nuclear translocation and binding to the -1 kb promoter of EGFR. Together these results suggested that activation of the PI3K/Akt pathway leads to phosphorylation of YB-1 at Ser102, resulting in up-regulation of EGFR gene expression. Here we propose that Akt, YB-1, and EGFR may all function in the same pathway to promote breast cancer cell growth.
URI: http://hdl.handle.net/2429/18400
Series/Report no. UBC Retrospective Theses Digitization Project [http://www.library.ubc.ca/archives/retro_theses/]

This item appears in the following Collection(s)

Show full item record

All items in cIRcle are protected by copyright, with all rights reserved.

UBC Library
1961 East Mall
Vancouver, B.C.
Canada V6T 1Z1
Tel: 604-822-6375
Fax: 604-822-3893